TY  - JOUR

T1  - Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: post hoc analysis results from a phase III trial

JO  - American Journal of Clinical Dermatology

UR  - https://eprints.whiterose.ac.uk/id/eprint/202963

PY  - 2023/06/10

AU  - Siegfried EC

AU  - Cork MJ

AU  - Katoh N

AU  - Zhang H

AU  - Chuang C-C

AU  - Thomas RB

AU  - Rossi AB

AU  - Cyr SL

AU  - Zhang A

ED  - 

DO  - DOI: 10.1007/s40257-023-00791-7

PB  - Springer Science and Business Media LLC

VL  - 24

IS  - 5

SP  - 787

EP  - 798

Y2  - 2024/12/22

ER  -